PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34222479-12 2021 In addition, AC-YVAD-CMK treatment significantly reduced the expression of GSDMD in renal tissues compared to those observed in controls (P < 0.05). ac-yvad 13-20 gasdermin D Mus musculus 75-80 34222479-0 2021 Caspase-1-Inhibitor AC-YVAD-CMK Inhibits Pyroptosis and Ameliorates Acute Kidney Injury in a Model of Sepsis. ac-yvad 20-27 caspase 1 Mus musculus 0-9 8521409-6 1995 The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. ac-yvad 126-133 caspase 1 Mus musculus 55-58 8521409-6 1995 The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. ac-yvad 126-133 caspase 1 Mus musculus 112-115 8521409-6 1995 The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. ac-yvad 126-133 chemokine (C-X-C motif) ligand 9 Mus musculus 134-137 8521409-6 1995 The apoptosis induced by cisplatin treatment or murine ICE overexpression can be suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK or the apoptosis inhibitors bcl-2 or bcl-2-related bcl-XL gene. ac-yvad 126-133 BCL2-like 1 Mus musculus 189-195 34624334-8 2021 Caspase-1 and GSDMD expression levels in all hLEC groups changed with blue light exposure times (8, 16, 24, and 32 h) and were higher in the AC-YVAD-CMK and SWBL exposure groups than in the NC group. ac-yvad 141-148 caspase 1 Homo sapiens 0-9 34624334-8 2021 Caspase-1 and GSDMD expression levels in all hLEC groups changed with blue light exposure times (8, 16, 24, and 32 h) and were higher in the AC-YVAD-CMK and SWBL exposure groups than in the NC group. ac-yvad 141-148 gasdermin D Homo sapiens 14-19 34624334-9 2021 The immunofluorescence results revealed higher GSDMD-N expression in the cell membrane of both the AC-YVAD-CMK and SWBL exposure groups than in the NC group. ac-yvad 99-106 gasdermin D Homo sapiens 47-52 34222479-0 2021 Caspase-1-Inhibitor AC-YVAD-CMK Inhibits Pyroptosis and Ameliorates Acute Kidney Injury in a Model of Sepsis. ac-yvad 20-27 chemokine (C-X-C motif) ligand 9 Mus musculus 28-31 34222479-1 2021 Objective: To observe the protective effect of AC-YVAD-CMK on sepsis-induced acute kidney injury in mice and to explore its possible mechanisms primarily. ac-yvad 47-54 chemokine (C-X-C motif) ligand 9 Mus musculus 55-58 34222479-2 2021 Methods: Eighteen male C57BL/6 mice were randomly divided into sham-operated group (Control), cecal ligation and puncture group (CLP), and CLP model treated with AC-YVAD-CMK group (AC-YVAD-CMK) (n = 6 in each group). ac-yvad 162-169 chemokine (C-X-C motif) ligand 9 Mus musculus 170-173 33848524-7 2021 RESULTS: Inflammasome activation and oxidative stress were elevated in CECs following exposure to TNF-alpha and IFN-gamma, which resulted in cell death by pyroptosis as determined by LDH release which was inhibited by the caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 242-249 tumor necrosis factor Homo sapiens 98-107 34222479-12 2021 In addition, AC-YVAD-CMK treatment significantly reduced the expression of GSDMD in renal tissues compared to those observed in controls (P < 0.05). ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 35227133-8 2022 Also, the IL-1 receptor antagonist, IL1RA, and caspase-1 inhibitor, Ac-YVAD, both inhibited MUC5AC secretion induced by cholesterol crystals. ac-yvad 68-75 caspase 1 Homo sapiens 47-56 35227133-8 2022 Also, the IL-1 receptor antagonist, IL1RA, and caspase-1 inhibitor, Ac-YVAD, both inhibited MUC5AC secretion induced by cholesterol crystals. ac-yvad 68-75 mucin 5AC, oligomeric mucus/gel-forming Homo sapiens 92-98 33647825-2 2021 Therefore, we aimed to elucidate the mechanism of Caspase-1 in in murine models of aGVHD through specific inhibition of its activity with the decoy peptide Ac-YVAD-CMK. ac-yvad 156-163 caspase 1 Mus musculus 50-59 33647825-2 2021 Therefore, we aimed to elucidate the mechanism of Caspase-1 in in murine models of aGVHD through specific inhibition of its activity with the decoy peptide Ac-YVAD-CMK. ac-yvad 156-163 chemokine (C-X-C motif) ligand 9 Mus musculus 164-167 33647825-7 2021 Thus, we demonstrate that inhibition of Caspase-1 by Ac-YVAD-CMK mitigates murine aGVHD by regulating Th1/Th17/Treg balance and attenuating its characteristic proinflammatory state. ac-yvad 53-60 caspase 1 Mus musculus 40-49 33647825-7 2021 Thus, we demonstrate that inhibition of Caspase-1 by Ac-YVAD-CMK mitigates murine aGVHD by regulating Th1/Th17/Treg balance and attenuating its characteristic proinflammatory state. ac-yvad 53-60 chemokine (C-X-C motif) ligand 9 Mus musculus 61-64 35563469-7 2022 Results: We report here that EMD, like the inflammasome (NLRP3) and CAS1 specific inhibitors-MCC950 and Ac-YVAD-cmk, respectively-lowered the LPS-induced expression of NLRP3 in primary macrophages (EMD: p = 0.0232; MCC950: p = 0.0426; Ac-YVAD-cmk: p = 0.0317). ac-yvad 104-111 caspase 1 Mus musculus 68-72 35563469-7 2022 Results: We report here that EMD, like the inflammasome (NLRP3) and CAS1 specific inhibitors-MCC950 and Ac-YVAD-cmk, respectively-lowered the LPS-induced expression of NLRP3 in primary macrophages (EMD: p = 0.0232; MCC950: p = 0.0426; Ac-YVAD-cmk: p = 0.0317). ac-yvad 104-111 NLR family, pyrin domain containing 3 Mus musculus 168-173 33848524-7 2021 RESULTS: Inflammasome activation and oxidative stress were elevated in CECs following exposure to TNF-alpha and IFN-gamma, which resulted in cell death by pyroptosis as determined by LDH release which was inhibited by the caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 242-249 interferon gamma Homo sapiens 112-121 33848524-7 2021 RESULTS: Inflammasome activation and oxidative stress were elevated in CECs following exposure to TNF-alpha and IFN-gamma, which resulted in cell death by pyroptosis as determined by LDH release which was inhibited by the caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 242-249 caspase 1 Homo sapiens 222-231 30897338-5 2019 C57/BL6 mouse pups were randomized to receive daily intraperitoneal injections of Ac-YVAD-CMK, an irreversible caspase-1 inhibitor, or placebo during exposure to room air or hyperoxia (85% O2) for 10 days. ac-yvad 82-89 chemokine (C-X-C motif) ligand 9 Mus musculus 90-93 33509083-12 2021 Moreover, AC-YVAD-CMK promoted membrane transport of GluA1 in APP/PS1 mice. ac-yvad 10-17 presenilin 1 Mus musculus 66-69 31181224-9 2019 In this context, both si-AIM2 and Ac-YVAD-CMK treatments effectively maintained neuronal viability, as demonstrated by the decreased percentage of cells with pyroptosis and release of lactate dehydrogenase (LDH), accompanied by weak immunoreactivity and a decreased number of AIM2-caspase-1 positive neurons. ac-yvad 34-41 absent in melanoma 2 Mus musculus 276-280 31181224-9 2019 In this context, both si-AIM2 and Ac-YVAD-CMK treatments effectively maintained neuronal viability, as demonstrated by the decreased percentage of cells with pyroptosis and release of lactate dehydrogenase (LDH), accompanied by weak immunoreactivity and a decreased number of AIM2-caspase-1 positive neurons. ac-yvad 34-41 caspase 1 Mus musculus 281-290 31381888-7 2019 Pharmacologic inhibition with Ac-YVAD-cmk of caspase 1, a critical component of the NLRP3 inflammasome, prevents DICER1 dysregulation- and dsRNA-induced osteoblast cell death. ac-yvad 30-37 caspase 1 Homo sapiens 45-54 31381888-7 2019 Pharmacologic inhibition with Ac-YVAD-cmk of caspase 1, a critical component of the NLRP3 inflammasome, prevents DICER1 dysregulation- and dsRNA-induced osteoblast cell death. ac-yvad 30-37 NLR family pyrin domain containing 3 Homo sapiens 84-89 31381888-7 2019 Pharmacologic inhibition with Ac-YVAD-cmk of caspase 1, a critical component of the NLRP3 inflammasome, prevents DICER1 dysregulation- and dsRNA-induced osteoblast cell death. ac-yvad 30-37 dicer 1, ribonuclease III Homo sapiens 113-119 31352322-0 2019 Ac-YVAD-cmk improves neurological function by inhibiting caspase-1-mediated inflammatory response in the intracerebral hemorrhage of rats. ac-yvad 0-7 caspase 1 Rattus norvegicus 57-66 31352322-3 2019 Therefore, we aimed to investigate the effects of caspase-1 inhibitor Ac-YVAD-cmk on ICH. ac-yvad 70-77 caspase 1 Rattus norvegicus 50-59 31352322-8 2019 RESULTS: Ac-YVAD-cmk inhibited the activation of pro-caspase-1 and decreased brain edema, in association with decreasing activated microglia and the expression of inflammation-related factors at 24 h post-ICH. ac-yvad 9-16 caspase 1 Rattus norvegicus 53-62 31352322-9 2019 Consequently, Ac-YVAD-cmk reduced the release of mature IL-1beta/IL-18 in perihematoma, improved the behavioral performance, and alleviated microglia in perihematoma region in ICH rats. ac-yvad 14-21 interleukin 1 beta Rattus norvegicus 56-64 31352322-9 2019 Consequently, Ac-YVAD-cmk reduced the release of mature IL-1beta/IL-18 in perihematoma, improved the behavioral performance, and alleviated microglia in perihematoma region in ICH rats. ac-yvad 14-21 interleukin 18 Rattus norvegicus 65-70 31352325-8 2019 To investigate whether the activation of inflammasome participates in the liver damage induced by TP, a single dose of Ac-Yvad-Cmk (Caspase-1 inhibitor) was injected before TP administration. ac-yvad 119-126 chemokine (C-X-C motif) ligand 9 Mus musculus 127-130 31352325-8 2019 To investigate whether the activation of inflammasome participates in the liver damage induced by TP, a single dose of Ac-Yvad-Cmk (Caspase-1 inhibitor) was injected before TP administration. ac-yvad 119-126 caspase 1 Mus musculus 132-141 31352325-9 2019 Ac-Yvad-Cmk pretreatment effectively prevented the increase of Cleaved Caspase-1 and inhibited the maturity of IL-1beta. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 31352325-9 2019 Ac-Yvad-Cmk pretreatment effectively prevented the increase of Cleaved Caspase-1 and inhibited the maturity of IL-1beta. ac-yvad 0-7 caspase 1 Mus musculus 71-80 31352325-9 2019 Ac-Yvad-Cmk pretreatment effectively prevented the increase of Cleaved Caspase-1 and inhibited the maturity of IL-1beta. ac-yvad 0-7 interleukin 1 beta Mus musculus 111-119 31352325-10 2019 Additional studies revealed that Ac-Yvad-Cmk pretreatment decreased the recruitment of neutrophils and inhibited the production of massive pro-inflammatory factors. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 caspase 1 Rattus norvegicus 40-48 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 interleukin 1 alpha Rattus norvegicus 173-181 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 interleukin 18 Rattus norvegicus 183-188 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 high mobility group box 1 Rattus norvegicus 194-199 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 transforming growth factor alpha Rattus norvegicus 221-229 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 Rattus norvegicus 231-236 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 collagen type I alpha 1 chain Rattus norvegicus 238-244 31582897-5 2019 Besides, rats treated with the specific caspase1 inhibitor Ac-YVAD-CMK showed less inflammatory reaction and fibrosis, not only in the expression of proinflammatory factors IL-1beta, IL-18, and HMGB1 and fibrosis markers TGF-beta, PLOD2, COL1A1, and TIMP1 but also in the observation of HE staining, Sirius Red staining, and the transverse diameters of the right knees. ac-yvad 59-66 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 250-255 33493800-6 2021 The blockade of inflammasome activation by the inhibitor Ac-YVAD-CMK abrogated AIM2-mediated M1 polarization and the inhibition of tumor cell growth. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 33493800-6 2021 The blockade of inflammasome activation by the inhibitor Ac-YVAD-CMK abrogated AIM2-mediated M1 polarization and the inhibition of tumor cell growth. ac-yvad 57-64 absent in melanoma 2 Mus musculus 79-83 33509083-6 2021 APP/PS1 mice and Abeta1-42-induced hippocampal neurones were treated with AC-YVAD-CMK (caspase-1 inhibitor). ac-yvad 74-81 chemokine (C-X-C motif) ligand 9 Mus musculus 82-85 33509083-6 2021 APP/PS1 mice and Abeta1-42-induced hippocampal neurones were treated with AC-YVAD-CMK (caspase-1 inhibitor). ac-yvad 74-81 caspase 1 Mus musculus 87-96 33509083-11 2021 RESULTS: AC-YVAD-CMK treatment improved spatial learning and memory ability and reduced senile plaque deposition of APP/PS1 mice. ac-yvad 9-16 chemokine (C-X-C motif) ligand 9 Mus musculus 17-20 33509083-11 2021 RESULTS: AC-YVAD-CMK treatment improved spatial learning and memory ability and reduced senile plaque deposition of APP/PS1 mice. ac-yvad 9-16 presenilin 1 Mus musculus 120-123 33509083-12 2021 Moreover, AC-YVAD-CMK promoted membrane transport of GluA1 in APP/PS1 mice. ac-yvad 10-17 chemokine (C-X-C motif) ligand 9 Mus musculus 18-21 33509083-12 2021 Moreover, AC-YVAD-CMK promoted membrane transport of GluA1 in APP/PS1 mice. ac-yvad 10-17 glutamate receptor, ionotropic, AMPA1 (alpha 1) Mus musculus 53-58 33217525-9 2021 The expression of GSDMD and IL-1beta protein levels were also decrease after treated by caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 108-115 gasdermin D Mus musculus 18-23 33217525-9 2021 The expression of GSDMD and IL-1beta protein levels were also decrease after treated by caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 108-115 interleukin 1 alpha Mus musculus 28-36 33217525-9 2021 The expression of GSDMD and IL-1beta protein levels were also decrease after treated by caspase-1 inhibitor Ac-YVAD-cmk. ac-yvad 108-115 caspase 1 Mus musculus 88-97 32201254-10 2020 AIM2 knockout (KO) and Ac-YVAD-CMK-induced caspase-1 inhibition in mice significantly improved cognitive function and reversed brain volume in the hippocampus relative to those in stroke mice. ac-yvad 23-30 chemokine (C-X-C motif) ligand 9 Mus musculus 31-34 32201254-10 2020 AIM2 knockout (KO) and Ac-YVAD-CMK-induced caspase-1 inhibition in mice significantly improved cognitive function and reversed brain volume in the hippocampus relative to those in stroke mice. ac-yvad 23-30 caspase 1 Mus musculus 43-52 32366053-5 2020 As inhibitors, sodium orthovanadate (general inhibitor of tyrosine phosphatases), AC-YVAD-CMK (caspase-1 inhibitor) or AZ10606120 (purinergic receptor P2X7R inhibitor) were applied after LPS priming. ac-yvad 82-89 C-X-C motif chemokine ligand 9 Homo sapiens 90-93 31429348-9 2019 Ac-YVAD-cmk or increasing extracellular K+ blocked the activation of caspase-1 and attenuated the release of IL-18. ac-yvad 0-7 caspase 1 Homo sapiens 69-78 31429348-9 2019 Ac-YVAD-cmk or increasing extracellular K+ blocked the activation of caspase-1 and attenuated the release of IL-18. ac-yvad 0-7 interleukin 18 Homo sapiens 109-114 30571969-4 2019 We showed in three psoriasis-like models that inflammatory caspases are activated, and accordingly, caspase 1/11 invalidation or pharmacological inhibition by Ac-YVAD-CMK (i.e., Ac-Tyr-Val-Ala-Asp-chloromethylketone) injection induced a decrease in ear thickness, erythema, scaling, inflammatory cytokine expression, and immune cell infiltration in mice. ac-yvad 159-166 caspase 1 Mus musculus 100-109 30559669-3 2018 This study was performed in rats with dinitrobenzenesulfonic acid (DNBS)-induced colitis, to investigate how the direct blockade of NLRP3 inflammasome with an irreversible inhibitor (INF39) compares with Ac-YVAD-cmk (YVAD, caspase-1 inhibitor) and anakinra (IL-1beta receptor antagonist), acting downstream on NLRP3 signaling. ac-yvad 204-211 NLR family, pyrin domain containing 3 Rattus norvegicus 132-137 30911553-12 2019 Meanwhile, Ac-YVAD-CMK, BAY11-7082, or NAC attenuated HG- and H/R-induced H9C2 cell injury with LPS stimulated by reversing the activation of NLRP3 inflammasome-mediated pyroptosis. ac-yvad 11-18 NLR family, pyrin domain containing 3 Rattus norvegicus 142-147 30761127-7 2019 In parallel, the enteropathy induced by p31-43 in vivo did not occur in the absence of NLRP3 or caspase 1 and was inhibited by administration of the caspase 1 inhibitor Ac-YVAD-cmk. ac-yvad 169-176 unconventional SNARE in the ER 1 homolog (S. cerevisiae) Mus musculus 40-43 30761127-7 2019 In parallel, the enteropathy induced by p31-43 in vivo did not occur in the absence of NLRP3 or caspase 1 and was inhibited by administration of the caspase 1 inhibitor Ac-YVAD-cmk. ac-yvad 169-176 caspase 1 Mus musculus 149-158 30944281-4 2019 We tested two inhibitors [the caspase-1 inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-cmk; hereafter referred to as YVAD), which can mitigate the LPS-induced increases in CD54 expression, and polymyxin B (PMB), which suppresses the effect of LPS by binding to its lipid moiety (i.e., the toxic component of LPS)]. ac-yvad 93-100 caspase 1 Homo sapiens 30-39 30944281-4 2019 We tested two inhibitors [the caspase-1 inhibitor acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-cmk; hereafter referred to as YVAD), which can mitigate the LPS-induced increases in CD54 expression, and polymyxin B (PMB), which suppresses the effect of LPS by binding to its lipid moiety (i.e., the toxic component of LPS)]. ac-yvad 93-100 intercellular adhesion molecule 1 Homo sapiens 186-190 30496753-7 2019 The selective NLRP3 inflammasome inhibitor Ac-YVAD-CMK exhibited similar anti-inflammatory and antidepressant effects like ketamine. ac-yvad 43-50 NLR family pyrin domain containing 3 Homo sapiens 14-19 30496753-7 2019 The selective NLRP3 inflammasome inhibitor Ac-YVAD-CMK exhibited similar anti-inflammatory and antidepressant effects like ketamine. ac-yvad 43-50 C-X-C motif chemokine ligand 9 Homo sapiens 51-54 30496753-8 2019 Combination of ketamine and Ac-YVAD-CMK showed no enhanced anti-inflammatory and antidepressant effects than ketamine or Ac-YVAD-CMK administration alone. ac-yvad 28-35 C-X-C motif chemokine ligand 9 Homo sapiens 36-39 30276509-5 2019 We used the NLRP3 inhibitor MCC950 and the caspase-1 inhibitor Ac-YVAD-CMK to study the role of the NLRP3/caspase-1 pathway in pyroptosis and cognitive deficits in a mouse model of SAE. ac-yvad 63-70 chemokine (C-X-C motif) ligand 9 Mus musculus 71-74 30276509-9 2019 In addition, administration of MCC950 or Ac-YVAD-CMK rescues cognitive deficits and ameliorates increased hippocampal NLRP3-mediated neuronal pyroptosis and pro-inflammatory cytokines. ac-yvad 41-48 chemokine (C-X-C motif) ligand 9 Mus musculus 49-52 30276509-9 2019 In addition, administration of MCC950 or Ac-YVAD-CMK rescues cognitive deficits and ameliorates increased hippocampal NLRP3-mediated neuronal pyroptosis and pro-inflammatory cytokines. ac-yvad 41-48 NLR family, pyrin domain containing 3 Mus musculus 118-123 30670928-4 2018 In this study, we examined the effect of Ac-YVAD-cmk, a potent caspase-1-specific inhibitor, on renal function and histology in cisplatin-treated mice and explored its underlying mechanisms. ac-yvad 41-48 caspase 1 Mus musculus 63-72 30670928-6 2018 Administration of Ac-YVAD-cmk inhibited caspase-3 activation as well as caspase-1 activation and attenuated apoptotic cell death, as assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, in the kidneys of cisplatin-treated mice. ac-yvad 18-25 caspase 3 Mus musculus 40-49 30670928-6 2018 Administration of Ac-YVAD-cmk inhibited caspase-3 activation as well as caspase-1 activation and attenuated apoptotic cell death, as assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling, in the kidneys of cisplatin-treated mice. ac-yvad 18-25 caspase 1 Mus musculus 72-81 30670928-10 2018 Taken together, these results suggest that caspase-1 inhibition by Ac-YVAD-cmk protects against cisplatin-induced nephrotoxicity through inhibition of renal tubular cell apoptosis, oxidative stress, and inflammatory responses. ac-yvad 67-74 caspase 1 Mus musculus 43-52 29886252-10 2018 Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. ac-yvad 0-7 caspase 1 Mus musculus 127-136 30473634-12 2018 However, this response was ameliorated by inhibition of the inflammasome with Ac-Tyr-Val-Ala-Asp-Chloromethylketone (Ac-YVAD-CMK). ac-yvad 117-124 chemokine (C-X-C motif) ligand 9 Mus musculus 125-128 30410928-0 2018 AC-YVAD-CMK Inhibits Pyroptosis and Improves Functional Outcome after Intracerebral Hemorrhage. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 30410928-5 2018 We tested a well-known selective inhibitor of caspase-1, AC-YVAD-CMK, which has previously been found to have neuroprotective effects in ICH mice model, to ascertain its effects on the activation of inflammasomes mediated pyroptosis. ac-yvad 57-64 caspase 1 Mus musculus 46-55 30410928-5 2018 We tested a well-known selective inhibitor of caspase-1, AC-YVAD-CMK, which has previously been found to have neuroprotective effects in ICH mice model, to ascertain its effects on the activation of inflammasomes mediated pyroptosis. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 30410928-6 2018 Our results showed that AC-YVAD-CMK could reduce caspase-1 activation and inhibit IL-1beta production and maturation, but has no effect on NLRP3 expression, an upstream inflammatory complex. ac-yvad 24-31 chemokine (C-X-C motif) ligand 9 Mus musculus 32-35 30410928-6 2018 Our results showed that AC-YVAD-CMK could reduce caspase-1 activation and inhibit IL-1beta production and maturation, but has no effect on NLRP3 expression, an upstream inflammatory complex. ac-yvad 24-31 caspase 1 Mus musculus 49-58 30410928-6 2018 Our results showed that AC-YVAD-CMK could reduce caspase-1 activation and inhibit IL-1beta production and maturation, but has no effect on NLRP3 expression, an upstream inflammatory complex. ac-yvad 24-31 interleukin 1 beta Mus musculus 82-90 30410928-7 2018 AC-YVAD-CMK administration also resulted in reduction in M1-type microglia polarization around the hematoma, while increasing the number of M2-type cells. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 30410928-8 2018 Furthermore, AC-YVAD-CMK treated mice showed some recovery of neurological function after hemorrhage especially at the hyperacute and subacute stage resulting in some degree of limb movement. ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 30410928-9 2018 In conclusion, we are of the view that AC-YVAD-CMK could inhibit pyroptosis, decrease the secretion or activation of inflammatory factors, and affect the polarization of microglia resulting in improvement of neurological function after ICH. ac-yvad 39-46 chemokine (C-X-C motif) ligand 9 Mus musculus 47-50 29886252-10 2018 Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. ac-yvad 0-7 interleukin 1 beta Mus musculus 188-196 29886252-10 2018 Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. ac-yvad 0-7 interleukin 18 Mus musculus 201-206 29886252-10 2018 Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. ac-yvad 0-7 PYD and CARD domain containing Mus musculus 249-252 28855128-4 2017 By using Ac-YVAD-CMK, a highly selective caspase-1 inhibitor, to inhibit inflammation reaction involved in allograft rejection in a rat model. ac-yvad 9-16 caspase 1 Rattus norvegicus 41-50 30138921-12 2018 CONCLUSION: Collectively, our results showed that pyroptosis is involved in the pathogenesis of alcohol-induced gastritis and that caspase-1 inhibitor Ac-yvad-cmk could effectively decrease the damage caused by alcohol, making it a potentially promising agent for the treatment of alcoholic gastritis. ac-yvad 151-158 caspase 1 Homo sapiens 131-140 30138921-12 2018 CONCLUSION: Collectively, our results showed that pyroptosis is involved in the pathogenesis of alcohol-induced gastritis and that caspase-1 inhibitor Ac-yvad-cmk could effectively decrease the damage caused by alcohol, making it a potentially promising agent for the treatment of alcoholic gastritis. ac-yvad 151-158 C-X-C motif chemokine ligand 9 Homo sapiens 159-162 28990231-9 2017 Moreover, IFI16-induced tumour cell death promoted the recruitment of inflammasome complex to enhance tumour inhibition, but the caspase-1 inhibitor Ac-YVAD-CMK (50 mumol/L) could suppress this process in HCC. ac-yvad 149-156 caspase 1 Homo sapiens 129-138 28990231-9 2017 Moreover, IFI16-induced tumour cell death promoted the recruitment of inflammasome complex to enhance tumour inhibition, but the caspase-1 inhibitor Ac-YVAD-CMK (50 mumol/L) could suppress this process in HCC. ac-yvad 149-156 C-X-C motif chemokine ligand 9 Homo sapiens 157-160 29382416-0 2017 [Caspase-1 inhibitor AC-YVAD-CMK blocks IL-1beta secretion of bone marrow-derived macrophages induced by Acinetobacter baumannii]. ac-yvad 21-28 chemokine (C-X-C motif) ligand 9 Mus musculus 29-32 29382416-1 2017 Objective To explore the effect of caspase-1 selective inhibitor AC-YVAD-CMK on IL-1beta secretion of bone marrow-derived macrophages (BMDMs) induced by Acinetobacter baumannii (A. baumannii). ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 29382416-5 2017 The role of caspase-1 in the secretion of IL-1beta was tested by AC-YVAD-CMK treatment to block caspase-1. ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 29382416-10 2017 Mature IL-1beta secretion was blocked by AC-YVAD-CMK either in vitro or in vivo. ac-yvad 41-48 chemokine (C-X-C motif) ligand 9 Mus musculus 49-52 29382416-11 2017 The damage of lung induced by A. baumannii infection in mice was ameliorated by AC-YVAD-CMK. ac-yvad 80-87 chemokine (C-X-C motif) ligand 9 Mus musculus 88-91 29382416-12 2017 Conclusion AC-YVAD-CMK alleviates pulmonary pathological damage by reducing the caspase-1-mediated IL-1beta secretion. ac-yvad 11-18 chemokine (C-X-C motif) ligand 9 Mus musculus 19-22 29941706-9 2018 Ac-YVAD-cmk blocked the activation of caspase-1 and subsequently attenuated IL-1beta secretion (181.00 +- 45.24 pg/ml in LPS + MPA + YVAD group vs. 588.00 +- 41.99 pg/ml in LPS + MPA group, P = 0.014). ac-yvad 0-7 caspase 1 Homo sapiens 38-47 29941706-9 2018 Ac-YVAD-cmk blocked the activation of caspase-1 and subsequently attenuated IL-1beta secretion (181.00 +- 45.24 pg/ml in LPS + MPA + YVAD group vs. 588.00 +- 41.99 pg/ml in LPS + MPA group, P = 0.014). ac-yvad 0-7 interleukin 1 beta Homo sapiens 76-84 29725399-3 2018 Additionally, the human breast cancer MDA-MB-231 cell line was treated with the Caspase-1 small molecule inhibitor Ac-YVAD-CMK, following which the changes to Caspase-1 protein expression were detected via western blotting. ac-yvad 115-122 caspase 1 Homo sapiens 80-89 29725399-3 2018 Additionally, the human breast cancer MDA-MB-231 cell line was treated with the Caspase-1 small molecule inhibitor Ac-YVAD-CMK, following which the changes to Caspase-1 protein expression were detected via western blotting. ac-yvad 115-122 C-X-C motif chemokine ligand 9 Homo sapiens 123-126 29725399-3 2018 Additionally, the human breast cancer MDA-MB-231 cell line was treated with the Caspase-1 small molecule inhibitor Ac-YVAD-CMK, following which the changes to Caspase-1 protein expression were detected via western blotting. ac-yvad 115-122 caspase 1 Homo sapiens 159-168 29725399-6 2018 Treatment with the Ac-YVAD-CMK markedly decreased the protein expression of Caspase-1 in MDA-MB-231 cells, and the difference was statistically significant (P<0.05). ac-yvad 19-26 C-X-C motif chemokine ligand 9 Homo sapiens 27-30 29725399-6 2018 Treatment with the Ac-YVAD-CMK markedly decreased the protein expression of Caspase-1 in MDA-MB-231 cells, and the difference was statistically significant (P<0.05). ac-yvad 19-26 caspase 1 Homo sapiens 76-85 29725399-7 2018 Following this treatment of Ac-YVAD-CMK cells, the proliferation and invasion abilities markedly increased, while the apoptotic levels significantly decreased (P<0.05). ac-yvad 28-35 C-X-C motif chemokine ligand 9 Homo sapiens 36-39 27705930-6 2016 Administration of berberine inhibited the viability, migration and invasion capacity of HepG2 cells through the induction of pyroptosis both in vitro and in vivo, which was attenuated by caspase-1 inhibitor Ac-YVAD-CMK. ac-yvad 207-214 caspase 1 Homo sapiens 187-196 28482444-4 2017 RAW264.7 cells pretreated with various concentrations (0, 5, 10, 25, 50, 75, 100, 200 mumol/L) of AC-YVAD-CMK for 2 h, and stimulated by 1 mg/L Pg LPS for 24 h in the third group. ac-yvad 98-105 chemokine (C-X-C motif) ligand 9 Mus musculus 106-109 28482444-7 2017 Results: It is observed that treatment with 5, 10, 25, 50, 75, 100, 200 mumol/L AC-YVAD-CMK did not significantly affect the viability of RAW264.7 cells. ac-yvad 80-87 chemokine (C-X-C motif) ligand 9 Mus musculus 88-91 28482444-10 2017 After stimulated by Pg LPS, mRNA and protein expression of IL-1beta (P<0.01, P<0.01) and NALP3 (P<0.01, P<0.01) significantly increased; but the expression of IL-1beta (P=0.002, P=0.027) and NALP3 (P<0.01, P<0.01) were decreased when pretreated with AC-YVAD-CMK. ac-yvad 268-275 interleukin 1 beta Mus musculus 59-67 28482444-10 2017 After stimulated by Pg LPS, mRNA and protein expression of IL-1beta (P<0.01, P<0.01) and NALP3 (P<0.01, P<0.01) significantly increased; but the expression of IL-1beta (P=0.002, P=0.027) and NALP3 (P<0.01, P<0.01) were decreased when pretreated with AC-YVAD-CMK. ac-yvad 268-275 NLR family, pyrin domain containing 3 Mus musculus 95-100 28245402-0 2017 [Caspase1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice]. ac-yvad 20-27 caspase 1 Mus musculus 1-9 28245402-0 2017 [Caspase1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice]. ac-yvad 20-27 chemokine (C-X-C motif) ligand 9 Mus musculus 28-31 28245402-1 2017 OBJECTIVE: To explore the effect of Caspase 1 inhibitor Ac-YVAD-CMK on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation(allo-HSCT) and its mechanism. ac-yvad 56-63 caspase 1 Mus musculus 36-45 28245402-1 2017 OBJECTIVE: To explore the effect of Caspase 1 inhibitor Ac-YVAD-CMK on acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation(allo-HSCT) and its mechanism. ac-yvad 56-63 chemokine (C-X-C motif) ligand 9 Mus musculus 64-67 28245402-7 2017 RESULTS: Ac-YVAD-CMK could alleviate murine aGVHD and pathological injury, decreare the incidence and severity of aGVHD in recipient mice. ac-yvad 9-16 chemokine (C-X-C motif) ligand 9 Mus musculus 17-20 28245402-10 2017 CONCLUSION: Ac-YVAD-CMK can improve aGVHD by inhibiting Caspase 1 and reducing the release of some inflammatory cytokines, thereby alleviated the aGVHD pathological damage. ac-yvad 12-19 chemokine (C-X-C motif) ligand 9 Mus musculus 20-23 28245402-10 2017 CONCLUSION: Ac-YVAD-CMK can improve aGVHD by inhibiting Caspase 1 and reducing the release of some inflammatory cytokines, thereby alleviated the aGVHD pathological damage. ac-yvad 12-19 caspase 1 Mus musculus 56-65 28903766-11 2017 Administration of AC-YVAD-CMK, a caspase-1 inhibitor, reduced the expression of IL-1beta and IL-18 and the number of PI-positive cells, attenuated brain edema, and improved neurological function, which was also observed in fluoxetine-treated rats. ac-yvad 18-25 caspase 1 Rattus norvegicus 33-42 28903766-11 2017 Administration of AC-YVAD-CMK, a caspase-1 inhibitor, reduced the expression of IL-1beta and IL-18 and the number of PI-positive cells, attenuated brain edema, and improved neurological function, which was also observed in fluoxetine-treated rats. ac-yvad 18-25 interleukin 1 beta Rattus norvegicus 80-88 28903766-11 2017 Administration of AC-YVAD-CMK, a caspase-1 inhibitor, reduced the expression of IL-1beta and IL-18 and the number of PI-positive cells, attenuated brain edema, and improved neurological function, which was also observed in fluoxetine-treated rats. ac-yvad 18-25 interleukin 18 Rattus norvegicus 93-98 28247334-5 2017 Results showed that high mRNA and protein expression levels of NLRP3 inflammasome components were observed in the injected side of the LPS- and 6-OHDA-induced PD rats; Ac-YVAD-CMK inhibited the mRNA and protein expression of NLRP3 inflammasome components in both LPS- and 6-OHDA-induced PD rats. ac-yvad 168-175 NLR family, pyrin domain containing 3 Rattus norvegicus 225-230 27705930-6 2016 Administration of berberine inhibited the viability, migration and invasion capacity of HepG2 cells through the induction of pyroptosis both in vitro and in vivo, which was attenuated by caspase-1 inhibitor Ac-YVAD-CMK. ac-yvad 207-214 C-X-C motif chemokine ligand 9 Homo sapiens 215-218 26663311-11 2016 Necrotic-like cell death was also suppressed by this compound and the caspase-1 inhibitor Ac-YVAD-CMK, indicating that histones triggered ECFC pyroptosis. ac-yvad 90-97 caspase 1 Homo sapiens 70-79 28078039-11 2016 The inhibitors of NLRP3 (Glyburide) and caspase-1 (AC-YVAD-CMK) alone or in combination were used to pre-treat the hepatic cells, which revealed that the pyroptosis rate was decreased and the cell damage alleviated. ac-yvad 51-58 caspase 1 Mus musculus 40-49 28078039-11 2016 The inhibitors of NLRP3 (Glyburide) and caspase-1 (AC-YVAD-CMK) alone or in combination were used to pre-treat the hepatic cells, which revealed that the pyroptosis rate was decreased and the cell damage alleviated. ac-yvad 51-58 chemokine (C-X-C motif) ligand 9 Mus musculus 59-62 27121255-5 2016 Mice were then continued on HFD for another 12 weeks, without (HFD) or with (HFD-YVAD) treatment with the caspase-1 inhibitor Ac-YVAD-cmk (40 mg kg(-1) per day). ac-yvad 126-133 caspase 1 Mus musculus 106-115 27053298-4 2016 The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment. ac-yvad 141-148 interleukin 1 beta Mus musculus 54-76 27053298-4 2016 The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment. ac-yvad 141-148 interleukin 6 Mus musculus 78-82 27053298-4 2016 The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment. ac-yvad 141-148 interleukin 18 Mus musculus 88-93 27053298-4 2016 The increased levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-18 following cold-stress injury were decreased by AC-YVAD-CMK, but not omeprazole, pretreatment. ac-yvad 141-148 chemokine (C-X-C motif) ligand 9 Mus musculus 149-152 27053298-5 2016 The increased expression of CD68 in gastric tissues was inhibited significantly by AC-YVAD-CMK pretreatment. ac-yvad 83-90 CD68 antigen Mus musculus 28-32 27053298-5 2016 The increased expression of CD68 in gastric tissues was inhibited significantly by AC-YVAD-CMK pretreatment. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 27053298-7 2016 AC-YVAD-CMK pretreatment significantly inhibited cold-restraint stress-induced increases in the expression of phosphorylated IkappaB-alpha and P38. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 27053298-7 2016 AC-YVAD-CMK pretreatment significantly inhibited cold-restraint stress-induced increases in the expression of phosphorylated IkappaB-alpha and P38. ac-yvad 0-7 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 125-138 27053298-7 2016 AC-YVAD-CMK pretreatment significantly inhibited cold-restraint stress-induced increases in the expression of phosphorylated IkappaB-alpha and P38. ac-yvad 0-7 mitogen-activated protein kinase 14 Mus musculus 143-146 27053298-8 2016 General anatomy and histological results showed the protective effect of AC-YVAD-CMK on ethanol-induced acute gastric injury. ac-yvad 73-80 chemokine (C-X-C motif) ligand 9 Mus musculus 81-84 27053298-9 2016 Overall, our results showed that the caspase-1 inhibitor AC-YVAD-CMK protected against acute gastric injury in mice by affecting the NLRP3 inflammasome and attenuating inflammatory processes and apoptosis. ac-yvad 57-64 caspase 1 Mus musculus 37-46 27053298-9 2016 Overall, our results showed that the caspase-1 inhibitor AC-YVAD-CMK protected against acute gastric injury in mice by affecting the NLRP3 inflammasome and attenuating inflammatory processes and apoptosis. ac-yvad 57-64 chemokine (C-X-C motif) ligand 9 Mus musculus 65-68 27053298-9 2016 Overall, our results showed that the caspase-1 inhibitor AC-YVAD-CMK protected against acute gastric injury in mice by affecting the NLRP3 inflammasome and attenuating inflammatory processes and apoptosis. ac-yvad 57-64 NLR family, pyrin domain containing 3 Mus musculus 133-138 27053298-0 2016 The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. ac-yvad 24-31 caspase 1 Mus musculus 4-13 27053298-0 2016 The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. ac-yvad 24-31 chemokine (C-X-C motif) ligand 9 Mus musculus 32-35 27053298-0 2016 The caspase-1 inhibitor AC-YVAD-CMK attenuates acute gastric injury in mice: involvement of silencing NLRP3 inflammasome activities. ac-yvad 24-31 NLR family, pyrin domain containing 3 Mus musculus 102-107 27053298-3 2016 Survival rates and histological evidence of gastric injury of mice pretreated with AC-YVAD-CMK or omeprazole, and exposed to cold-restraint stress, improved significantly relative to the vehicle group. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 26739627-10 2016 Il1r1-knockout mice or treatment with Ac-YVAD-cmk decreased the IL-17A production and subsequent airway inflammation. ac-yvad 38-45 interleukin 17A Mus musculus 64-70 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 caspase 1 Homo sapiens 26-35 27010539-8 2016 Caspase-1 inhibitor, Ac-YVAD-CMK and deletion of Nlrp3 or Asc gene abolished MSU-induced decreases in renal sodium excretion and MBF. ac-yvad 21-28 rhotekin 2 Mus musculus 129-132 26415803-11 2015 The specific caspase-1 inhibitor Ac-YVAD-CMK inhibited the activation of caspase-1 and pyroptotic cell death. ac-yvad 33-40 caspase 1 Mus musculus 13-22 26415803-11 2015 The specific caspase-1 inhibitor Ac-YVAD-CMK inhibited the activation of caspase-1 and pyroptotic cell death. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 26415803-11 2015 The specific caspase-1 inhibitor Ac-YVAD-CMK inhibited the activation of caspase-1 and pyroptotic cell death. ac-yvad 33-40 caspase 1 Mus musculus 73-82 26415803-12 2015 Ac-YVAD-CMK also reduced the lung injury, pulmonary edema and total protein in bronchoalveolar lavage fluid (BALF). ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 interleukin 18 Mus musculus 138-143 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 tumor necrosis factor Mus musculus 145-173 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 tumor necrosis factor Mus musculus 176-188 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 high mobility group box 1 Mus musculus 190-215 26415803-13 2015 In addition, Ac-YVAD-CMK significantly inhibited interleukin-alpha2 (IL-1alpha2) release both in serum and BALF and reduced the levels of IL-18, tumor necrosis factor-alpha+- (TNF-alpha+-), High Mobility Group Box 1 (HMGB1) in BALF during LPS-induced ALI/ARDS. ac-yvad 13-20 high mobility group box 1 Mus musculus 217-222 26415803-14 2015 CONCLUSIONS: This study reported AM pyroptosis during LPS-induced ALI/ARDS in mice and has demonstrated that Ac-YVAD-CMK can prevent AM-induced pyroptosis and lung injury. ac-yvad 109-116 chemokine (C-X-C motif) ligand 9 Mus musculus 117-120 24925806-6 2014 While several inhibitors are available for caspase-1 blocking experiments, in this study we show effects of two commonly used caspase inhibitors: z-VAD-fmk and ac-YVAD-cmk on secretion of pro-inflammatory cytokines: IL-1beta, TNFalpha, IL-8 and IL-6 in whole blood stimulated with LPS. ac-yvad 160-167 C-X-C motif chemokine ligand 9 Homo sapiens 168-171 24925806-6 2014 While several inhibitors are available for caspase-1 blocking experiments, in this study we show effects of two commonly used caspase inhibitors: z-VAD-fmk and ac-YVAD-cmk on secretion of pro-inflammatory cytokines: IL-1beta, TNFalpha, IL-8 and IL-6 in whole blood stimulated with LPS. ac-yvad 160-167 interleukin 1 beta Homo sapiens 216-224 24925806-6 2014 While several inhibitors are available for caspase-1 blocking experiments, in this study we show effects of two commonly used caspase inhibitors: z-VAD-fmk and ac-YVAD-cmk on secretion of pro-inflammatory cytokines: IL-1beta, TNFalpha, IL-8 and IL-6 in whole blood stimulated with LPS. ac-yvad 160-167 tumor necrosis factor Homo sapiens 226-234 24925806-6 2014 While several inhibitors are available for caspase-1 blocking experiments, in this study we show effects of two commonly used caspase inhibitors: z-VAD-fmk and ac-YVAD-cmk on secretion of pro-inflammatory cytokines: IL-1beta, TNFalpha, IL-8 and IL-6 in whole blood stimulated with LPS. ac-yvad 160-167 C-X-C motif chemokine ligand 8 Homo sapiens 236-240 24925806-6 2014 While several inhibitors are available for caspase-1 blocking experiments, in this study we show effects of two commonly used caspase inhibitors: z-VAD-fmk and ac-YVAD-cmk on secretion of pro-inflammatory cytokines: IL-1beta, TNFalpha, IL-8 and IL-6 in whole blood stimulated with LPS. ac-yvad 160-167 interleukin 6 Homo sapiens 245-249 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 C-X-C motif chemokine ligand 9 Homo sapiens 23-26 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 caspase 1 Homo sapiens 41-50 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 interleukin 1 beta Homo sapiens 98-106 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 tumor necrosis factor Homo sapiens 131-139 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 interleukin 6 Homo sapiens 141-145 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 C-X-C motif chemokine ligand 8 Homo sapiens 150-154 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 caspase 1 Homo sapiens 41-48 24925806-7 2014 We demonstrate ac-YVAD-cmk is a specific caspase-1 inhibitor resulting in pronounced decreases in IL-1beta and less suppression of TNFalpha, IL-6 and IL-8, while pan-caspase inhibitor, z-VAD-fmk, only weakly suppressed Il-1beta while acting strongly on the other three cytokines. ac-yvad 15-22 interleukin 1 beta Homo sapiens 219-227 25445379-6 2015 Next, using a caspase-1 inhibitor (Ac-YVAD-CMK) to block caspase-1 activation in vitro and in vivo, we further demonstrated that X-ray irradiation may inhibit proliferation, induce senescence of NSPCs through caspase-1 activation. ac-yvad 35-42 caspase 1 Homo sapiens 14-23 25445379-6 2015 Next, using a caspase-1 inhibitor (Ac-YVAD-CMK) to block caspase-1 activation in vitro and in vivo, we further demonstrated that X-ray irradiation may inhibit proliferation, induce senescence of NSPCs through caspase-1 activation. ac-yvad 35-42 C-X-C motif chemokine ligand 9 Homo sapiens 43-46 25445379-6 2015 Next, using a caspase-1 inhibitor (Ac-YVAD-CMK) to block caspase-1 activation in vitro and in vivo, we further demonstrated that X-ray irradiation may inhibit proliferation, induce senescence of NSPCs through caspase-1 activation. ac-yvad 35-42 caspase 1 Homo sapiens 57-66 25445379-6 2015 Next, using a caspase-1 inhibitor (Ac-YVAD-CMK) to block caspase-1 activation in vitro and in vivo, we further demonstrated that X-ray irradiation may inhibit proliferation, induce senescence of NSPCs through caspase-1 activation. ac-yvad 35-42 caspase 1 Homo sapiens 57-66 24279434-8 2014 Pretreatment with the NLRP3 inflammasome inhibitor Ac-YVAD-CMK significantly abrogated the depressive-like behaviors induced by lipopolysaccharide. ac-yvad 51-58 NLR family, pyrin domain containing 3 Mus musculus 22-27 24279434-8 2014 Pretreatment with the NLRP3 inflammasome inhibitor Ac-YVAD-CMK significantly abrogated the depressive-like behaviors induced by lipopolysaccharide. ac-yvad 51-58 chemokine (C-X-C motif) ligand 9 Mus musculus 59-62 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 leptin Homo sapiens 50-56 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 caspase 1 Homo sapiens 70-79 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 leptin Homo sapiens 107-113 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 interleukin 18 Homo sapiens 117-122 24275551-11 2014 Analysis of the action of caspase-1 revealed that leptin up regulates caspase-1 activity and the effect of leptin on IL-18 release is prevented by caspase-1 inhibitor (Ac-YVAD-cmk). ac-yvad 168-175 caspase 1 Homo sapiens 70-79 24184660-5 2013 The cytotoxic effect of Delta8-THC was significantly prevented by a caspase-1 inhibitor Ac-YVAD-cmk but not a caspase-3 inhibitor z-DEVD-fmk. ac-yvad 88-95 caspase 1 Mus musculus 68-77 21921832-8 2012 Lastly, the functional significance of inflammasome activation following burn injury was tested in mice treated with the specific caspase-1 inhibitor, AC-YVAD-CMK. ac-yvad 151-158 caspase 1 Mus musculus 130-139 23839215-4 2013 Treating monocytes with the caspase-1 inhibitor Ac-YVAD-CMK reduced IL-1beta release, suggesting a role for the inflammasome in T. gondii-induced IL-1beta production. ac-yvad 48-55 caspase 1 Homo sapiens 28-37 23839215-4 2013 Treating monocytes with the caspase-1 inhibitor Ac-YVAD-CMK reduced IL-1beta release, suggesting a role for the inflammasome in T. gondii-induced IL-1beta production. ac-yvad 48-55 interleukin 1 beta Homo sapiens 68-76 23839215-4 2013 Treating monocytes with the caspase-1 inhibitor Ac-YVAD-CMK reduced IL-1beta release, suggesting a role for the inflammasome in T. gondii-induced IL-1beta production. ac-yvad 48-55 interleukin 1 beta Homo sapiens 146-154 23011098-6 2013 Furthermore, treatment of cells with the caspase-1 inhibitor Ac-YVAD-CMK dramatically decreased the percentage of pyroptosis. ac-yvad 61-68 caspase 1 Mus musculus 41-50 23011098-6 2013 Furthermore, treatment of cells with the caspase-1 inhibitor Ac-YVAD-CMK dramatically decreased the percentage of pyroptosis. ac-yvad 61-68 chemokine (C-X-C motif) ligand 9 Mus musculus 69-72 21921832-8 2012 Lastly, the functional significance of inflammasome activation following burn injury was tested in mice treated with the specific caspase-1 inhibitor, AC-YVAD-CMK. ac-yvad 151-158 chemokine (C-X-C motif) ligand 9 Mus musculus 159-162 21921832-15 2012 Surprisingly, we found that blocking caspase-1 activation with AC-YVAD-CMK in vivo caused significantly higher mortality in burn-injured mice (P < 0.01). ac-yvad 63-70 caspase 1 Mus musculus 37-46 21921832-15 2012 Surprisingly, we found that blocking caspase-1 activation with AC-YVAD-CMK in vivo caused significantly higher mortality in burn-injured mice (P < 0.01). ac-yvad 63-70 chemokine (C-X-C motif) ligand 9 Mus musculus 71-74 21677131-6 2011 This was further substantiated by the use of a specific caspase-1 inhibitor, Ac-YVAD-CMK. ac-yvad 77-84 caspase 1 Mus musculus 56-65 21677131-6 2011 This was further substantiated by the use of a specific caspase-1 inhibitor, Ac-YVAD-CMK. ac-yvad 77-84 chemokine (C-X-C motif) ligand 9 Mus musculus 85-88 21677131-7 2011 Wild-type mice treated with Ac-YVAD-CMK (10 mg/kg s.c. twice daily, initiated at time of CLP) did not have impaired clearance of a Pseudomonas challenge compared with that of sham mice and had significantly improved bacterial clearance compared with that of untreated CLP mice. ac-yvad 28-35 chemokine (C-X-C motif) ligand 9 Mus musculus 36-39 20596246-0 2010 Ac-YVAD-CMK Decreases Blood-Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1beta in Intracerebral Hemorrhage Mouse Model. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 20660063-9 2010 Moreover, when TNFalpha-induced secretion/production of IL-1beta from adipocytes was inhibited by the IL-1 converting enzyme (ICE-1) inhibitor II (Ac-YVAD-CMK), insulin resistance was prevented. ac-yvad 147-154 tumor necrosis factor Rattus norvegicus 15-23 20660063-9 2010 Moreover, when TNFalpha-induced secretion/production of IL-1beta from adipocytes was inhibited by the IL-1 converting enzyme (ICE-1) inhibitor II (Ac-YVAD-CMK), insulin resistance was prevented. ac-yvad 147-154 interleukin 1 beta Rattus norvegicus 56-64 20823759-8 2010 Caspase-1 was blocked using the selective inhibitors Ac-YVAD-CMK and VRTXSD727. ac-yvad 53-60 caspase 1 Mus musculus 0-9 20823759-8 2010 Caspase-1 was blocked using the selective inhibitors Ac-YVAD-CMK and VRTXSD727. ac-yvad 53-60 chemokine (C-X-C motif) ligand 9 Mus musculus 61-64 20823759-12 2010 Pretreatment with Ac-YVAD-CMK significantly reduced mechanical allodynia and thermal hyperalgesia. ac-yvad 18-25 chemokine (C-X-C motif) ligand 9 Mus musculus 26-29 20596246-0 2010 Ac-YVAD-CMK Decreases Blood-Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1beta in Intracerebral Hemorrhage Mouse Model. ac-yvad 0-7 caspase 1 Mus musculus 68-77 20596246-0 2010 Ac-YVAD-CMK Decreases Blood-Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1beta in Intracerebral Hemorrhage Mouse Model. ac-yvad 0-7 interleukin 1 beta Mus musculus 92-109 20596246-3 2010 In this study, we tested the neuroprotective effect of Ac-YVAD-CMK, a known selective caspase-1 inhibitor, in a mouse model of intracerebral hemorrhage (ICH). ac-yvad 55-62 chemokine (C-X-C motif) ligand 9 Mus musculus 63-66 20596246-3 2010 In this study, we tested the neuroprotective effect of Ac-YVAD-CMK, a known selective caspase-1 inhibitor, in a mouse model of intracerebral hemorrhage (ICH). ac-yvad 55-62 caspase 1 Mus musculus 86-95 20596246-5 2010 Ac-YVAD-CMK or vehicle was administered into the left lateral ventricle 20 min before ICH modeling. ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 20596246-8 2010 At 24 h after ICH, Ac-YVAD-CMK treatment significantly reduced brain edema and improved neurological functions. ac-yvad 19-26 chemokine (C-X-C motif) ligand 9 Mus musculus 27-30 20596246-10 2010 We conclude that Ac-YVAD-CMK protects the brain against ICH-induced injury, and the neuroprotective effect may result from anti-inflammation-induced blood-brain barrier protection. ac-yvad 17-24 chemokine (C-X-C motif) ligand 9 Mus musculus 25-28 19875734-1 2009 BACKGROUND AND PURPOSE: We examined the effects of a caspase-1 inhibitor, N-Ac-Tyr-Val-Ala-Asp-chloromethyl ketone (Ac-YVAD-CMK), on neurogenic pulmonary edema in the endovascular perforation model of subarachnoid hemorrhage (SAH) in mice. ac-yvad 116-123 chemokine (C-X-C motif) ligand 9 Mus musculus 124-127 19875734-5 2009 RESULTS: Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1beta and caspase-3 and the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive pulmonary endothelial cells, preventing neurogenic pulmonary edema. ac-yvad 33-40 chemokine (C-X-C motif) ligand 9 Mus musculus 41-44 19875734-5 2009 RESULTS: Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1beta and caspase-3 and the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive pulmonary endothelial cells, preventing neurogenic pulmonary edema. ac-yvad 33-40 interleukin 1 beta Mus musculus 110-127 19875734-5 2009 RESULTS: Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1beta and caspase-3 and the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive pulmonary endothelial cells, preventing neurogenic pulmonary edema. ac-yvad 33-40 caspase 3 Mus musculus 132-141 19875734-5 2009 RESULTS: Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1beta and caspase-3 and the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling-positive pulmonary endothelial cells, preventing neurogenic pulmonary edema. ac-yvad 33-40 deoxynucleotidyltransferase, terminal Mus musculus 160-196 19875734-8 2009 CONCLUSIONS: We report for the first time that Ac-YVAD-CMK prevents lung cell apoptosis and neurogenic pulmonary edema after SAH in mice. ac-yvad 47-54 chemokine (C-X-C motif) ligand 9 Mus musculus 55-58 15379993-8 2004 These results suggested that the protection of Ac-YVAD-cmk might not be due to its inhibition of caspase-1. ac-yvad 47-54 cytidine/uridine monophosphate kinase 1 Homo sapiens 55-58 19461019-7 2009 Although both dosages of Ac-YVAD-CMK attenuated the mature IL-1beta induction, only high-dose treatment group significantly inhibited the phosphorylation of JNK, MMP-9 induction, and ZO-1 degradation. ac-yvad 25-32 chemokine (C-X-C motif) ligand 9 Mus musculus 33-36 19461019-7 2009 Although both dosages of Ac-YVAD-CMK attenuated the mature IL-1beta induction, only high-dose treatment group significantly inhibited the phosphorylation of JNK, MMP-9 induction, and ZO-1 degradation. ac-yvad 25-32 interleukin 1 beta Mus musculus 59-67 19461019-7 2009 Although both dosages of Ac-YVAD-CMK attenuated the mature IL-1beta induction, only high-dose treatment group significantly inhibited the phosphorylation of JNK, MMP-9 induction, and ZO-1 degradation. ac-yvad 25-32 matrix metallopeptidase 9 Mus musculus 162-167 19461019-9 2009 The neurovascular protection of Ac-YVAD-CMK may be provided by the inhibition of JNK-mediated MMP-9 induction and the consequent preservation of tight junction protein ZO-1. ac-yvad 32-39 chemokine (C-X-C motif) ligand 9 Mus musculus 40-43 19461019-9 2009 The neurovascular protection of Ac-YVAD-CMK may be provided by the inhibition of JNK-mediated MMP-9 induction and the consequent preservation of tight junction protein ZO-1. ac-yvad 32-39 mitogen-activated protein kinase 8 Mus musculus 81-84 19461019-9 2009 The neurovascular protection of Ac-YVAD-CMK may be provided by the inhibition of JNK-mediated MMP-9 induction and the consequent preservation of tight junction protein ZO-1. ac-yvad 32-39 matrix metallopeptidase 9 Mus musculus 94-99 19461019-9 2009 The neurovascular protection of Ac-YVAD-CMK may be provided by the inhibition of JNK-mediated MMP-9 induction and the consequent preservation of tight junction protein ZO-1. ac-yvad 32-39 tight junction protein 1 Mus musculus 145-172 16225757-2 2005 METHODS: Mouse models of ischemic ARF were treated with the specific ICE inhibitor AC-YVAD-CMK. ac-yvad 83-90 caspase 1 Mus musculus 69-72 16225757-2 2005 METHODS: Mouse models of ischemic ARF were treated with the specific ICE inhibitor AC-YVAD-CMK. ac-yvad 83-90 chemokine (C-X-C motif) ligand 9 Mus musculus 91-94 16225757-3 2005 A renal function assay and renal morphological studies were employed to estimate the renal protective effect of AC-YVAD-CMK. ac-yvad 112-119 chemokine (C-X-C motif) ligand 9 Mus musculus 120-123 16225757-11 2005 AC-YVAD-CMK therapy alleviated the clinical features of ARF, and increased the survival rate (P<0.01). ac-yvad 0-7 chemokine (C-X-C motif) ligand 9 Mus musculus 8-11 16225757-12 2005 Furthermore, AC-YVAD-CMK therapy also decreased ICE activity, mature IL-18 protein expression, and IFN-gamma mRNA expression in renal tissue (P<0.05). ac-yvad 13-20 chemokine (C-X-C motif) ligand 9 Mus musculus 21-24 16225757-12 2005 Furthermore, AC-YVAD-CMK therapy also decreased ICE activity, mature IL-18 protein expression, and IFN-gamma mRNA expression in renal tissue (P<0.05). ac-yvad 13-20 caspase 1 Mus musculus 48-51 16225757-12 2005 Furthermore, AC-YVAD-CMK therapy also decreased ICE activity, mature IL-18 protein expression, and IFN-gamma mRNA expression in renal tissue (P<0.05). ac-yvad 13-20 interleukin 18 Mus musculus 69-74 16225757-12 2005 Furthermore, AC-YVAD-CMK therapy also decreased ICE activity, mature IL-18 protein expression, and IFN-gamma mRNA expression in renal tissue (P<0.05). ac-yvad 13-20 interferon gamma Mus musculus 99-108 16225757-13 2005 CONCLUSION: The selective ICE inhibitor AC-YVAD-CMK can effectively protect the kidney from acute ischemic lesions. ac-yvad 40-47 caspase 1 Mus musculus 26-29 16225757-13 2005 CONCLUSION: The selective ICE inhibitor AC-YVAD-CMK can effectively protect the kidney from acute ischemic lesions. ac-yvad 40-47 chemokine (C-X-C motif) ligand 9 Mus musculus 48-51 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 0-7 cytidine/uridine monophosphate kinase 1 Homo sapiens 8-11 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 0-7 MAPK associated protein 1 Homo sapiens 74-79 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 0-7 cytidine/uridine monophosphate kinase 1 Homo sapiens 122-125 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 114-121 cytidine/uridine monophosphate kinase 1 Homo sapiens 8-11 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 114-121 MAPK associated protein 1 Homo sapiens 74-79 15379993-10 2004 Ac-YVAD-cmk also completely blocked in vitro protein nitration induced by SIN-1 or peroxynitrite, suggesting that Ac-YVAD-cmk may interact with peroxynitrite directly. ac-yvad 114-121 cytidine/uridine monophosphate kinase 1 Homo sapiens 122-125 12874316-8 2003 The specific caspase-1 inhibitor Ac-YVAD-CMK blocked the early IL-18 release in AM infected with the virulent strain. ac-yvad 33-40 caspase 1 Homo sapiens 13-22 15460444-3 2004 Treatment with caspase-1 inhibitor, Ac-YVAD-CMK, or caspase-3 inhibitor, Z-DEVD-FMK, partially inhibited ginsenoside Rh2-induced cell death but almost suppressed the cleavage of the 116 kDa PARP into a 85 kDa fragment. ac-yvad 36-43 cytidine/uridine monophosphate kinase 1 Homo sapiens 44-47 15460444-3 2004 Treatment with caspase-1 inhibitor, Ac-YVAD-CMK, or caspase-3 inhibitor, Z-DEVD-FMK, partially inhibited ginsenoside Rh2-induced cell death but almost suppressed the cleavage of the 116 kDa PARP into a 85 kDa fragment. ac-yvad 36-43 Rh associated glycoprotein Homo sapiens 117-120 12874316-8 2003 The specific caspase-1 inhibitor Ac-YVAD-CMK blocked the early IL-18 release in AM infected with the virulent strain. ac-yvad 33-40 C-X-C motif chemokine ligand 9 Homo sapiens 41-44 12874316-8 2003 The specific caspase-1 inhibitor Ac-YVAD-CMK blocked the early IL-18 release in AM infected with the virulent strain. ac-yvad 33-40 interleukin 18 Homo sapiens 63-68 12874324-8 2003 Presence of the caspase 1 inhibitor Ac-YVAD-CMK significantly blocked the leukotoxin-induced lysis of monocytes only. ac-yvad 36-43 caspase 1 Homo sapiens 16-25 12738769-7 2003 We present evidence suggesting that interleukin (IL)-1beta plays a significant role in mediating the effects of Abeta(1-40) because Abeta(1-40) increased hippocampal IL-1beta and because several effects of Abeta(1-40) were inhibited by the caspase-1 inhibitor Ac-YVAD-CMK. ac-yvad 260-267 interleukin 1 beta Homo sapiens 36-58 12956396-8 2003 The coronary arterial tissue IL-1beta level was significantly decreased in the animals treated with Ac-YVAD-cmk (0.254 +/- 0.162 vs. 0.463 +/- 0.307 pg/mg protein, p < 0.05), and exhibited a positive linear correlation (r = 0.581, p = 0.013) with the in-stent plaque volume. ac-yvad 100-107 interleukin-1 beta Sus scrofa 29-37 12956396-9 2003 In conclusion, intracoronary administration of Ac-YVAD-cmk before coronary artery stenting results in significantly decreased neointimal hyperplasia due to the inhibition of local IL-1beta production and decreased neointimal apoptosis. ac-yvad 47-54 interleukin-1 beta Sus scrofa 180-188 10877921-10 2000 Total graft volume, P-zone volume, total number of neuron-like cells, and number of DARPP-32-positive cells were increased, compared to control, in the group receiving Ac-YVAD-cmk-treated graft tissue. ac-yvad 168-175 protein phosphatase 1, regulatory (inhibitor) subunit 1B Rattus norvegicus 84-92 11238606-7 2001 In organ culture the caspase-1 inhibitor Ac-YVAD-cmk, but not control peptide, potently inhibited the epidermal LC migration that occurs in this system, and reduced spontaneous migration of LC was observed in skin derived from caspase-1-deficient mice. ac-yvad 41-48 caspase 1 Mus musculus 21-30 11238606-7 2001 In organ culture the caspase-1 inhibitor Ac-YVAD-cmk, but not control peptide, potently inhibited the epidermal LC migration that occurs in this system, and reduced spontaneous migration of LC was observed in skin derived from caspase-1-deficient mice. ac-yvad 41-48 caspase 1 Mus musculus 227-236 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. ac-yvad 33-40 C-X-C motif chemokine ligand 9 Homo sapiens 41-44 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. ac-yvad 33-40 caspase 3 Homo sapiens 46-55 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. ac-yvad 33-40 DNA polymerase epsilon 3, accessory subunit Homo sapiens 82-85 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. ac-yvad 33-40 tubulin polymerization promoting protein family member 3 Homo sapiens 90-93 10934034-8 2000 In the presence of z-DEVD-FMK or Ac-YVAD-CMK, caspase-3 was processed to both the p17 and p20 fragments in staurosporine-treated cells, but only to p20 fragment in the presence of z-VAD-FMK. ac-yvad 33-40 tubulin polymerization promoting protein family member 3 Homo sapiens 148-151 12620650-6 2003 This caspase-3 activity was inhibited in vitro by Ac-YVAD-cmk and Ac-DEVD-cmk caspase inhibitors. ac-yvad 50-57 caspase 3 Homo sapiens 5-14 12540519-5 2003 We herein examined whether pharmacological inhibition of the caspase-1 cascade, using Ac-Tyr-Val-Ala-Asp-CH(2)Cl (Ac-YVAD.cmk), after myocardial ischaemia have greater protective effects on myocardial ischaemia-reperfusion injury in diet-induced hypercholesterolaemic rabbits. ac-yvad 114-121 caspase-1 Oryctolagus cuniculus 61-70 12540519-14 2003 Ac-YVAD.cmk treatment resulted in a reduction not only of IL-1beta and caspase-1, but also of caspase-3 in the ischaemic myocardium in both normally fed and cholesterol-fed rabbits. ac-yvad 0-7 interleukin-1 beta Oryctolagus cuniculus 58-66 12540519-14 2003 Ac-YVAD.cmk treatment resulted in a reduction not only of IL-1beta and caspase-1, but also of caspase-3 in the ischaemic myocardium in both normally fed and cholesterol-fed rabbits. ac-yvad 0-7 caspase-1 Oryctolagus cuniculus 71-80 12540519-14 2003 Ac-YVAD.cmk treatment resulted in a reduction not only of IL-1beta and caspase-1, but also of caspase-3 in the ischaemic myocardium in both normally fed and cholesterol-fed rabbits. ac-yvad 0-7 caspase-3 Oryctolagus cuniculus 94-103 11704656-8 2001 Death of CHP100 cells induced by gp120 is also prevented by acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK; 10-100 microM), a second inhibitor of ICE, supporting the concept that the viral protein stimulates the conversion of the 31 kDa pro-IL-1beta in to the 17 kDa mature cytokine which is then secreted to cause death. ac-yvad 103-110 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 33-38 11704656-8 2001 Death of CHP100 cells induced by gp120 is also prevented by acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK; 10-100 microM), a second inhibitor of ICE, supporting the concept that the viral protein stimulates the conversion of the 31 kDa pro-IL-1beta in to the 17 kDa mature cytokine which is then secreted to cause death. ac-yvad 103-110 C-X-C motif chemokine ligand 9 Homo sapiens 111-114 11704656-8 2001 Death of CHP100 cells induced by gp120 is also prevented by acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK; 10-100 microM), a second inhibitor of ICE, supporting the concept that the viral protein stimulates the conversion of the 31 kDa pro-IL-1beta in to the 17 kDa mature cytokine which is then secreted to cause death. ac-yvad 103-110 caspase 1 Homo sapiens 154-157 11704656-8 2001 Death of CHP100 cells induced by gp120 is also prevented by acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK; 10-100 microM), a second inhibitor of ICE, supporting the concept that the viral protein stimulates the conversion of the 31 kDa pro-IL-1beta in to the 17 kDa mature cytokine which is then secreted to cause death. ac-yvad 103-110 interleukin 1 beta Homo sapiens 249-257 11408612-8 2001 Moreover, ROS generation depends on caspase-1-like activation because the Ac-YVAD-cho inhibitor abrogates CDDP-induced ROS in the c-Myc low-expressing clones. ac-yvad 74-81 caspase 1 Homo sapiens 36-45 11408612-8 2001 Moreover, ROS generation depends on caspase-1-like activation because the Ac-YVAD-cho inhibitor abrogates CDDP-induced ROS in the c-Myc low-expressing clones. ac-yvad 74-81 MYC proto-oncogene, bHLH transcription factor Homo sapiens 130-135 11015286-0 2000 Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses. ac-yvad 20-27 caspase 1 Rattus norvegicus 0-9 10844008-2 2000 We studied whether blockade of group I caspases, mainly caspase-1, using the inhibitor Ac-YVAD.cmk reduced infarct volume and produced prolonged neuroprotection. ac-yvad 87-94 caspase 1 Rattus norvegicus 56-65 9989786-6 1999 Furthermore, pretreating the cells with two caspase inhibitors (Ac-DEVD-cho and Ac-YVAD-cmk) could inhibit both cleavage/activation of PAK2 and DNA fragmentation induced by hyperosmotic shock. ac-yvad 80-87 p21 (RAC1) activated kinase 2 Homo sapiens 135-139 9717744-7 1998 Moreover, blockage of the activation of caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors of caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could substantially diminish the extent of heat shock-induced cleavage/activation of PAK2. ac-yvad 147-154 caspase 3 Homo sapiens 40-49 9990127-12 1999 On the other hand, the ac-YVAD-aldehyde tetrapeptide inhibitor that is dominantly effective on interleukin-1beta converting enzyme failed to block the apoptotic event initiated by LAO. ac-yvad 23-30 caspase 1 Homo sapiens 95-130 9923616-5 1999 In addition, the caspase inhibitors z-VAD.fmk, z-DEVD.fmk and Ac-YVAD.cmk also efficiently inhibited cathepsin B activity in vitro and in tissue culture cells at concentrations that are generally used to demonstrate the involvement of caspases. ac-yvad 62-69 cathepsin B Homo sapiens 101-112 9856788-4 1998 Whether the specific tetrapeptide ICE inhibitor Ac-YVAD-CMK affected gamma-irradiation-induced apoptosis in tumor cells was also examined. ac-yvad 48-55 caspase 1 Homo sapiens 34-37 9856788-4 1998 Whether the specific tetrapeptide ICE inhibitor Ac-YVAD-CMK affected gamma-irradiation-induced apoptosis in tumor cells was also examined. ac-yvad 48-55 cytidine/uridine monophosphate kinase 1 Homo sapiens 56-59 9856788-8 1998 The apoptotic cell death induced by gamma-irradiation was suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK. ac-yvad 103-110 caspase 1 Homo sapiens 89-92 9856788-8 1998 The apoptotic cell death induced by gamma-irradiation was suppressed by the tetrapeptide ICE inhibitor Ac-YVAD-CMK. ac-yvad 103-110 cytidine/uridine monophosphate kinase 1 Homo sapiens 111-114 9827536-8 1998 All newly described activities of cathepsin B, namely processing of caspase zymogens and induction of nuclear apoptosis, are inhibited by the synthetic peptide caspase inhibitors z-VAD.fmk, z-DEVD.fmk and to a lesser extent by Ac-YVAD.cmk. ac-yvad 227-234 cathepsin B Homo sapiens 34-45 9712143-7 1998 Moreover, blockage of activation of CPP32/caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors for caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could significantly attenuate the extent of cleavage/activation of PAK2 induced by UV irradiation. ac-yvad 150-157 caspase 3 Homo sapiens 36-41 9712143-7 1998 Moreover, blockage of activation of CPP32/caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors for caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could significantly attenuate the extent of cleavage/activation of PAK2 induced by UV irradiation. ac-yvad 150-157 caspase 3 Homo sapiens 42-51 9712143-7 1998 Moreover, blockage of activation of CPP32/caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors for caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could significantly attenuate the extent of cleavage/activation of PAK2 induced by UV irradiation. ac-yvad 150-157 caspase 1 Homo sapiens 124-132 9712143-7 1998 Moreover, blockage of activation of CPP32/caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors for caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could significantly attenuate the extent of cleavage/activation of PAK2 induced by UV irradiation. ac-yvad 150-157 p21 (RAC1) activated kinase 2 Homo sapiens 230-234 9717744-7 1998 Moreover, blockage of the activation of caspase-3 by pretreating the cells with two specific tetrapeptidic inhibitors of caspases (Ac-DEVD-cho and Ac-YVAD-cmk) could substantially diminish the extent of heat shock-induced cleavage/activation of PAK2. ac-yvad 147-154 p21 (RAC1) activated kinase 2 Homo sapiens 245-249 9459177-2 1997 Ac-YVAD-CMK or Ac-DEVD-CHO effectively prevented G-Rh2-induced DNA fragmentation, indicating the involvement of caspase-like proteases in the process of apoptosis. ac-yvad 0-7 cytidine/uridine monophosphate kinase 1 Homo sapiens 8-11 9565639-4 1998 In addition, TNF sensitization was also observed when the cells were pretreated with Ac-YVAD-cmk or zDEVD-fmk, which inhibits caspase-1- and caspase-3-like proteases, respectively. ac-yvad 85-92 tumor necrosis factor Mus musculus 13-16 9585109-4 1998 The IL-1beta converting enzyme (ICE) inhibitor Ac-YVAD-CMK annulled the adrenal response to LPS, but did not affect that to IL-1beta. ac-yvad 47-54 caspase 1 Rattus norvegicus 4-30 9585109-4 1998 The IL-1beta converting enzyme (ICE) inhibitor Ac-YVAD-CMK annulled the adrenal response to LPS, but did not affect that to IL-1beta. ac-yvad 47-54 caspase 1 Rattus norvegicus 32-35 9585109-4 1998 The IL-1beta converting enzyme (ICE) inhibitor Ac-YVAD-CMK annulled the adrenal response to LPS, but did not affect that to IL-1beta. ac-yvad 47-54 interleukin 1 beta Rattus norvegicus 4-12 9459177-2 1997 Ac-YVAD-CMK or Ac-DEVD-CHO effectively prevented G-Rh2-induced DNA fragmentation, indicating the involvement of caspase-like proteases in the process of apoptosis. ac-yvad 0-7 Rh associated glycoprotein Homo sapiens 51-54 9563681-13 1997 (5) Nocodazole-induced apoptosis in the deep cell layer can be blocked by the caspase-1,4,5 inhibitors Ac-YVAD-CHO and Ac-YVAD-CMK. ac-yvad 103-110 caspase a Danio rerio 78-87 9206994-5 1997 Transfection with the cowpox protease inhibitor crmA or culture in the presence of the synthetic ICE-specific inhibitor Ac-YVAD.cmk both prevent the DeltaPsim collapse and subsequent apoptosis. ac-yvad 120-127 caspase 1 Homo sapiens 97-100 9373772-7 1997 Contrary to expectations, the peptide aldehydes listed above and Ac-YVAD-Cmk, known as highly specific ICE inhibitors, did not inhibit the apoptosis of these cell types. ac-yvad 65-72 chemokine (C-X-C motif) ligand 9 Mus musculus 73-76 9070907-5 1997 Pretreatment of cells with ICE inhibitor II (Ac-YVAD-CMK), ICE inhibitor III (Z-Asp-2,6-dichlorobenzoyloxy-methylketone-Z-Asp-CH2-DCB+ ++), or ICE inhibitor IV (Ac-YVKD-CHO) (all at 10-100 microM) did not protect cells from hypoxic injury. ac-yvad 45-52 cytidine/uridine monophosphate kinase 1 Homo sapiens 53-56 8920897-5 1996 Injections of the tetrapeptide Ac-YVAD.cmk, more specific for the ICE-like subfamily of cysteine proteases but less cell permeable, also gave protection, but at higher doses and when injections started before that of anti-Fas antibody. ac-yvad 31-38 caspase 1 Mus musculus 66-69 8764657-3 1996 A peptide inhibitor of ICE-like protease activity, Ac-YVAD-chloromethylketone (Ac-YVAD-CMK), prevents K+ deprivation-induced apoptosis. ac-yvad 51-58 caspase 1 Homo sapiens 23-26 8764657-3 1996 A peptide inhibitor of ICE-like protease activity, Ac-YVAD-chloromethylketone (Ac-YVAD-CMK), prevents K+ deprivation-induced apoptosis. ac-yvad 51-58 C-X-C motif chemokine ligand 9 Homo sapiens 87-90 8764657-5 1996 Using fluorescent assays, we show that ROS production after K+ deprivation is blocked by actinomycin D, cycloheximide, and Ac-YVAD-CMK, suggesting that ROS act downstream of gene transcription, mRNA translation, and ICE activation. ac-yvad 123-130 C-X-C motif chemokine ligand 9 Homo sapiens 131-134 8764657-5 1996 Using fluorescent assays, we show that ROS production after K+ deprivation is blocked by actinomycin D, cycloheximide, and Ac-YVAD-CMK, suggesting that ROS act downstream of gene transcription, mRNA translation, and ICE activation. ac-yvad 123-130 caspase 1 Homo sapiens 216-219 9105050-7 1997 The irreversible IRP/caspase-inhibitor Ac-YVAD-cmk and the reversible IRP/caspase-inhibitor Ac-DEVD-CHO blocked the morphological changes, disorganization of plasma membrane phospholipids, DNA fragmentation, and loss of cell viability associated with TRAIL-induced apoptosis. ac-yvad 39-46 tumor necrosis factor (ligand) superfamily, member 10 Mus musculus 251-256 8947829-2 1996 The interleukin-1 beta converting enzyme (ICE)-like Ac-YVAD-MCA hydrolytic activity was increased about 6-fold by treatment with retinoic acid. ac-yvad 52-59 caspase 1 Mus musculus 4-40 8947829-2 1996 The interleukin-1 beta converting enzyme (ICE)-like Ac-YVAD-MCA hydrolytic activity was increased about 6-fold by treatment with retinoic acid. ac-yvad 52-59 caspase 1 Mus musculus 42-45